SOHM, Inc. Announces the Appointment of Wm. Dewey Rushing, former US FDA Investigator to its Advisory Board

Rhea-AI Summary

SOHM, Inc. (OTC PINK:SHMN) announced the expansion of its Advisory Board with the appointment of Wm. Dewey Rushing, a former U.S. FDA investigator, as an expert in Validation and Compliance. This move aims to bolster compliance and regulatory expertise, essential for the company's growth strategy. Mr. Rushing brings over 20 years of experience in pharmaceutical quality validation and cGMP compliance, further strengthening SOHM's commitment to portfolio diversification and expanding its foothold in the healthcare sector.

Positive

• Appointment of Wm. Dewey Rushing to Advisory Board strengthens compliance expertise.
• Rushing's extensive experience in pharmaceutical validation enhances regulatory oversight.
• The expansion of the Advisory Board supports SOHM's growth strategy.

Negative

• None.

CHINO HILLS, CA / ACCESSWIRE / February 23, 2022 / SOHM, Inc. (OTC PINK:SHMN), a Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today that it has expanded its Advisory Board with the signing of an engagement agreement with Wm. Dewey Rushing to serve on the Advisory Board as our expert on Validation and Compliance offering his extensive expertise in pharmaceutical Quality Validation and cGMP Compliance.

Mr. Baron Night, President and CEO of SOHM Inc. said, "Mr. Rushing's incredible background and experience in pharmaceutical validation and cGMP compliance is a crucial element needed on our Board of Advisory, "SOHM is expanding quickly, and it is imperative that we stay ahead of compliance and regulatory issues so that we can deliver the growth and valuation that our shareholders are expecting from us."

Mr. Rushing has over 20 years of experience in pharmaceutical Quality Validation and cGMP Compliance. He spent 4 years with the U.S. Food & Drug Administration as a Trained Investigator and instructor for the Los Angeles District. He is experienced in the technology transfer of biological and pharmaceutical products. Mr. Rushing also has extensive validation experience with equipment and facility validation; critical utility systems; process equipment; scale-up and transfer of biological processes; and facility design and start-up. He also has experience as an auditor for contract manufacturers and materials suppliers and is an exceptional technical writer with experience in authoring Master Plans, Protocols, and Quality Agreements.

Mr. Rushing has a B.A. Biology and B.S. Microbiology (1989) from Kansas State University, Manhattan, Kansas, and most recently completed requirements in the Master's in Science, Pharmaceutical Regulatory Affairs Program at San Diego State University, San Diego, CA.

SOHM is looking forward to the insight and expertise Mr. Rushing provides as they continue working towards portfolio diversification.

About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a vision "Globalè Prospèro" that tries to build continuous growth. SOHM manufacturing and marketing targets the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India as well as has strategic alliances with US manufacturing facilities. Although SOHM's generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To learn more about SOHM, Inc., visit www.SOHM.com

Safe Harbor Statement:
This news release contains "forward-looking statements", which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.

For more information, please contact:
SOHM, Inc.
714-522-6700

SOURCE: SOHM, Inc.

View source version on accesswire.com:
https://www.accesswire.com/690010/SOHM-Inc-Announces-the-Appointment-of-Wm-Dewey-Rushing-former-US-FDA-Investigator-to-its-Advisory-Board

FAQ

What is the significance of Wm. Dewey Rushing's appointment to SOHM's Advisory Board?

Wm. Dewey Rushing's appointment is significant as it enhances SOHM's compliance and regulatory oversight, crucial for its growth in the pharmaceutical industry.

How does Mr. Rushing's experience benefit SOHM, Inc.?

Mr. Rushing's experience in pharmaceutical quality validation and cGMP compliance will improve SOHM's adherence to regulatory standards, aiding in its expansion efforts.

What is SHMN's strategy for market growth following the Advisory Board expansion?

Following the Advisory Board expansion, SHMN aims to leverage improved compliance and regulatory practices to enhance its portfolio diversification and market presence.